Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 21, 2007

Morphotek Signs Development and Clinical Supply Deal with CMC Biopharmaceuticals

  • Morphotek okayed an agreement with CMC Biopharmaceuticals for GMP manufacturing and regulatory documentation support of MORAb-028, a therapeutic antibody targeting advanced melanoma and other cancers.

    MORAb-028 is a human IgM mAb that specifically recognizes a cell surface antigen over-expressed on a significant fraction of metastatic melanoma, brain cancers, and non-small-cell-lung carcinoma, according to Morphotek.

  • You’re all set! Thank you for subscribing to GEN Highlights.